STOCK TITAN

Xeris Biopharma Holdings, Inc. - XERS STOCK NEWS

Welcome to our dedicated page for Xeris Biopharma Holdings news (Ticker: XERS), a resource for investors and traders seeking the latest updates and insights on Xeris Biopharma Holdings stock.

Xeris Biopharma Holdings, Inc. (Symbol: XERS) is a pioneering biopharmaceutical company committed to developing and commercializing innovative therapies for patient populations in endocrinology, neurology, and gastroenterology. The company's mission is to revolutionize patient care by creating ultra-low volume, ready-to-use biotherapeutics delivered through patient-friendly injectable devices.

Xeris has successfully brought three groundbreaking products to market:

  • Gvoke: A ready-to-use liquid glucagon designed to treat severe hypoglycemia, providing a critical solution for diabetic patients.
  • Keveyis: The first FDA-approved therapy for primary periodic paralysis, offering relief for those suffering from this rare genetic disorder.
  • Recorlev: Approved by the FDA for the treatment of endogenous hypercortisolemia in adult patients with Cushing's Syndrome, addressing a previously unmet need in this patient population.

In addition to these commercial successes, Xeris continues to innovate with a robust pipeline of development programs. Utilizing its proprietary formulation technologies, XeriSol and XeriJect, the company aims to bring new therapies to market that ease the administration and increase the efficacy of injectable treatments.

Financially, Xeris Biopharma Holdings has shown significant growth and resilience in a competitive market. Their strategic partnerships and collaborations further bolster their developmental and commercial capabilities, ensuring a steady pipeline of innovative products aimed at improving patient outcomes.

Recent achievements and ongoing projects underline Xeris' commitment to enhancing the quality of life for millions of patients globally. Keep up with the latest updates and news about Xeris Biopharma Holdings, Inc. to stay informed about their ongoing advancements and performance in the biopharmaceutical industry.

Rhea-AI Summary

Xeris Pharmaceuticals (Nasdaq: XERS) has announced the grant of three new patents concerning its formulation technologies. The U.S. Patent and Trademark Office issued U.S. Patent Nos. 10,987,399 and 11,020,403, covering storage-stable formulations of pramlintide and benzodiazepines, respectively. Additionally, the China Intellectual Property Office granted Chinese Patent No. ZL201580042185.5 for pre-filled syringes utilizing Xeris’ XeriJect™ technology. These patents expand Xeris’ intellectual property portfolio, now totaling 121 patents worldwide, supporting innovation in therapies for diabetes and other conditions.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.32%
Tags
none
-
Rhea-AI Summary

Xeris Pharmaceuticals (Nasdaq: XERS) announces a significant milestone for Gvoke, a ready-to-use glucagon treatment for severe hypoglycemia, achieving extensive payor coverage. Approximately 91% of Medicare patients and 88% of commercially insured patients now have unrestricted access to Gvoke. The company emphasizes its commitment to affordable healthcare and effective market access strategies. The press release highlights the importance of ensuring access for patients, especially with children returning to school. Gvoke was FDA-approved in September 2019, and it is crucial for diabetes management.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-4.53%
Tags
none
-
Rhea-AI Summary

Xeris Pharmaceuticals, Inc. (Nasdaq: XERS) announced the FDA's approval of its Investigational New Drug Application (IND) for XeriSol levothyroxine, enabling the initiation of a Phase 1 clinical study for XP-8121. This study will assess the pharmacokinetics, safety, and tolerability of XeriSol's subcutaneous levothyroxine treatment for hypothyroidism. The company aims to address unmet needs in oral levothyroxine therapy by offering weekly subcutaneous injections to improve patient compliance and mitigate existing treatment challenges.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
3.4%
Tags
none
Rhea-AI Summary

Xeris Pharmaceuticals, Inc. (Nasdaq: XERS) announced its Q2 financial results for 2021, showcasing a 32% increase in Gvoke net sales, totaling $8.8 million. The company reported a net loss of $27.5 million, improving from a loss of $24.1 million in Q2 2020. The proposed acquisition of Strongbridge Biopharma is anticipated to close in Q4 2021, with a cash position of $116 million. Gvoke's prescription volume surged, reaching over 21,000, and a partnership with Tetris Pharma aims to commercialize Ogluo in Europe, potentially adding up to $71 million in future payments.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-12.98%
Tags
-
Rhea-AI Summary

Xeris Pharmaceuticals, Inc. (Nasdaq: XERS) reported its issued share capital as of July 28, 2021, consisting of 66,497,370 shares of common stock. The company also noted 5,081,323 stock options, 2,059,762 restricted stock units, 94,012 warrants, and $47,175,000 in convertible notes due 2025. Xeris, known for its innovative injectable therapeutic solutions, has technologies that improve the ease and stability of drug administration, including its commercial product, Gvoke®. The announcement also highlights upcoming SEC filings related to the acquisition of Strongbridge Biopharma.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-3.15%
Tags
none
-
Rhea-AI Summary

Xeris Pharmaceuticals, Inc. (Nasdaq: XERS) will release its second quarter 2021 financial results on August 5, 2021, before the U.S. market opens. A conference call will be held at 8:30 a.m. ET to discuss financial and operational results. Xeris specializes in ready-to-use injectable formulations, with its proprietary technologies such as XeriSol™ and XeriJect™, aimed at simplifying administration and enhancing stability. The company's first commercial product is Gvoke®. Investors can register for the call and access a replay later.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-5.37%
Tags
Rhea-AI Summary

Xeris Pharmaceuticals (Nasdaq: XERS) announced executive changes to strengthen its commercial strategy, particularly ahead of the acquisition of Strongbridge Biopharma. CFO Barry Deutsch has stepped down but will assist during the transition until the merger's expected completion in Q4 2021. Steven Pieper, with 20 years of healthcare finance experience, has been promoted to CFO. He previously helped launch Xeris's first commercial product, Gvoke®. The company continues to focus on innovative, ready-to-use injectable drug formulations to enhance patient care.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-5.37%
Tags
none
-
Rhea-AI Summary

Xeris Pharmaceuticals (Nasdaq: XERS) has entered an exclusive agreement with Tetris Pharma for the commercialization of Ogluo® in the European Economic Area, the UK, and Switzerland, aimed at treating severe hypoglycaemia in diabetes patients. Xeris is set to receive up to $71 million in milestone payments and royalties on net sales. The partnership is expected to enhance Ogluo's accessibility to insulin-dependent diabetes patients, where the demand is significant, yet current glucagon prescriptions remain low.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.29%
Tags
none
-
Rhea-AI Summary

Xeris Pharmaceuticals, Inc. (Nasdaq: XERS) disclosed that on July 1, 2021, it granted 80,250 restricted stock units to 37 new employees through its Inducement Equity Plan. This plan targets new hires as incentives for accepting employment. The stock options will vest over four years, with various vesting schedules based on employment duration. Xeris specializes in ready-to-use injectable formulations, aiming to simplify medication delivery and reduce healthcare costs. Its proprietary technologies, XeriSol™ and XeriJect™, enhance stability and ease of use for patients and providers.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-7.29%
Tags
none
Rhea-AI Summary

Xeris Pharmaceuticals (XERS) has announced an agreement to acquire Strongbridge Biopharma (SBBP) for approximately $267 million in stock and contingent value rights (CVRs). Strongbridge shareholders will receive a fixed exchange ratio of 0.7840 shares of the new entity, Xeris Biopharma Holdings, and potential CVRs based on sales milestones of KEVEYIS® and RECORLEV®. This merger aims to create a diversified biopharmaceutical company focused on rare diseases, enhancing revenue growth with commercial assets like Gvoke® and RECORLEV®. The transaction is expected to close in Q4 2021.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.92%
Tags

FAQ

What is the current stock price of Xeris Biopharma Holdings (XERS)?

The current stock price of Xeris Biopharma Holdings (XERS) is $3.49 as of December 20, 2024.

What is the market cap of Xeris Biopharma Holdings (XERS)?

The market cap of Xeris Biopharma Holdings (XERS) is approximately 527.7M.

What does Xeris Biopharma Holdings, Inc. specialize in?

Xeris focuses on developing and commercializing innovative therapies in endocrinology, neurology, and gastroenterology.

What are the main products of Xeris Biopharma?

Xeris' main products include Gvoke for severe hypoglycemia, Keveyis for primary periodic paralysis, and Recorlev for endogenous hypercortisolemia in Cushing's Syndrome.

What is Gvoke used for?

Gvoke is a ready-to-use liquid glucagon designed to treat severe hypoglycemia in diabetic patients.

What makes Xeris' therapies unique?

Xeris' therapies are unique due to their ultra-low volume, ready-to-use formulations delivered through patient-friendly injectable devices.

What proprietary technologies does Xeris use?

Xeris uses proprietary formulation technologies such as XeriSol and XeriJect to enhance the administration and efficacy of injectable treatments.

How many products has Xeris successfully commercialized?

Xeris has three commercially available products: Gvoke, Keveyis, and Recorlev.

What is Keveyis used for?

Keveyis is the first FDA-approved therapy for primary periodic paralysis, a rare genetic disorder.

What is Recorlev approved to treat?

Recorlev is approved by the FDA for the treatment of endogenous hypercortisolemia in adult patients with Cushing's Syndrome.

What are XeriSol and XeriJect?

XeriSol and XeriJect are Xeris' proprietary formulation technologies used to develop advanced injectable therapies.

Where can I find the latest news about Xeris Biopharma Holdings?

You can find the latest news about Xeris Biopharma Holdings on their official website and stock market news platforms like StockTitan.

Xeris Biopharma Holdings, Inc.

Nasdaq:XERS

XERS Rankings

XERS Stock Data

527.75M
141.54M
3.92%
43.81%
6.81%
Biotechnology
Pharmaceutical Preparations
Link
United States of America
CHICAGO